TL 13-112 |
| Catalog No.GC50561 |
TL 13-112 es un degradador potente y selectivo de ALK-PROTAC e inhibe la actividad de ALK con un valor IC50 de 0,14 nM. TL 13-112 también provoca la degradación de quinasas adicionales, incluidas Aurora A, FER, PTK2 y RPS6KA1 con valores IC50 de 8550 nM, 42,4 nM, 25,4 nM y 677 nM, respectivamente. TL 13-112 se compone de la conjugación de Ceritinib y el ligando Cereblon de Pomalidomida.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2229037-19-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Selective anaplastic lymphoma kinase (ALK) degrader (DC50 values are 10 and 40 nM in H3122 and Karpas 299 cells, respectively). Comprises the cereblon E3 ligase ligand Pomalidomide conjugated to an ALK inhibitor. Inhibits proliferation of ALK-positive cancer cell lines. Maximum degradation exhibited at 16 h. Negative control TL 13-110 also available.
Powell et al (2019) Chemically induced degradation of anaplastic lymphoma kinase (ALK). J.Med.Chem. 61 4249 PMID:29660984
Average Rating: 5 (Based on Reviews and 37 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *